BioVIE Drops After Phase 2, MSU Leads Hormonal Drug Modeling, Exercise After Cancer Cuts Recurrence, Rochester Leads Global Laser Science, and more...

Show notes

(0:10): [BioVie">https://www.brief.news/stories/2026/9/14/biovie-trial-tests-bezisterim-for-long-covid?utm\_source=brief-podcast&utm\_medium=episode-description">BioVie]( https://www.brief.news/stories/2026/9/14/ai-transforms-womens-health?utm\_source=brief-podcast&utm\_medium=episode-description">$12.8M]( https://www.brief.news/stories/2026/9/15/exercise-after-cancer-cuts-recurrence?utm\_source=brief-podcast&utm\_medium=episode-description">Exercise]( https://www.brief.news/stories/2026/9/15/rochester-leads-global-laser-science?utm\_source=brief-podcast&utm\_medium=episode-description">Rochester]( https://www.brief.news/stories/2026/9/16/atp-synthase-guards-calcium-balance?utm\_source=brief-podcast&utm\_medium=episode-description">Study]( https://www.brief.news/podcasts">https://www.brief.news. For more updates in your inbox each morning visit [www.brief.news]( https://www.brief.news">www.brief.news. Image credit: InvestorsHub